Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of skeletal muscle satellite cell proliferation. [GOC:ef, GOC:mtg_muscle, PMID:16607119]
Skeletal muscle satellite cells (SCs) are quiescent stem cells residing beneath the basal lamina of muscle fibers. They play a critical role in muscle regeneration by proliferating and differentiating into myoblasts, which fuse to form new muscle fibers. The regulation of SC proliferation is a tightly controlled process, involving a complex interplay of intrinsic and extrinsic factors.
**Intrinsic Factors:**
* **Transcription factors:** Myogenic regulatory factors (MRFs) such as Myf5, MyoD, and Myogenin are key regulators of SC proliferation and differentiation. Myf5 is required for SC specification, while MyoD promotes SC proliferation. Myogenin is essential for the terminal differentiation of myoblasts into myotubes.
* **Cell cycle regulators:** Cyclin-dependent kinases (CDKs) and their regulatory subunits, cyclins, control cell cycle progression. The expression of specific CDKs and cyclins is regulated during SC activation and proliferation.
* **MicroRNAs:** These small non-coding RNAs regulate gene expression at the post-transcriptional level. Several microRNAs have been implicated in the regulation of SC proliferation, including miR-206 and miR-133.
**Extrinsic Factors:**
* **Growth factors:** Several growth factors, including insulin-like growth factor 1 (IGF-1), fibroblast growth factor 2 (FGF2), and hepatocyte growth factor (HGF), promote SC proliferation. These factors activate signaling pathways that lead to the expression of genes involved in cell cycle progression.
* **Cytokines:** Inflammatory cytokines, such as TNF-α and IL-6, can both promote and inhibit SC proliferation depending on the context.
* **Extracellular matrix (ECM):** The ECM provides structural support and signaling cues for SCs. Laminin and collagen are major ECM components that influence SC adhesion, proliferation, and differentiation.
* **Mechanical stimuli:** Muscle stretching and contraction can activate SCs and promote their proliferation. This is mediated by mechanotransduction pathways involving integrins and focal adhesion kinases.
**Regulation of SC Proliferation During Muscle Regeneration:**
Upon muscle injury, quiescent SCs are activated and enter the cell cycle. This activation is triggered by signals released from damaged muscle fibers and inflammatory cells. SC proliferation is tightly controlled to ensure proper muscle regeneration. As SCs proliferate, they migrate to the site of injury and differentiate into myoblasts. Eventually, the proliferative pool of SCs is depleted, and differentiation becomes dominant, leading to the formation of new muscle fibers.
**Factors Influencing SC Proliferation:**
* **Age:** SC function declines with age, resulting in reduced regenerative capacity.
* **Disease:** Various muscle diseases, such as muscular dystrophy, can impair SC function and limit muscle regeneration.
* **Nutritional status:** Nutrients, such as amino acids and protein, are essential for SC proliferation and differentiation.
**Future Directions:**
* Understanding the complex interplay of intrinsic and extrinsic factors that regulate SC proliferation is crucial for developing therapies for muscle regeneration.
* Targeting specific pathways involved in SC activation, proliferation, and differentiation could lead to the development of novel regenerative therapies for muscle injuries and diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Peroxisome proliferator-activated receptor delta | A peroxisome proliferator-activated receptor delta that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q03181] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
gw 2433 | GW 2433: binds peroxisome proliferator-activated receptor alpha (PPARalpha); structure in first source | ||
clofibric acid | clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate. Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE. | aromatic ether; monocarboxylic acid; monochlorobenzenes | anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist |
pirinixic acid | pirinixic acid: structure | aryl sulfide; organochlorine compound; pyrimidines | |
methyleugenol | methyleugenol: structure | phenylpropanoid | |
myristic acid | Myristic Acid: A saturated 14-carbon fatty acid occurring in most animal and vegetable fats, particularly butterfat and coconut, palm, and nutmeg oils. It is used to synthesize flavor and as an ingredient in soaps and cosmetics. (From Dorland, 28th ed) tetradecanoate : A long-chain fatty acid anion that is the conjugate base of myristic acid; major species at pH 7.3. tetradecanoic acid : A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat. | long-chain fatty acid; straight-chain saturated fatty acid | algal metabolite; Daphnia magna metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite |
bezafibrate | aromatic ether; monocarboxylic acid; monocarboxylic acid amide; monochlorobenzenes | antilipemic drug; environmental contaminant; geroprotector; xenobiotic | |
fenofibric acid | fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate. fenofibric acid: RN given refers to parent cpd without isomeric designation; structure | aromatic ketone; chlorobenzophenone; monocarboxylic acid | drug metabolite; marine xenobiotic metabolite |
telmisartan | telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension. Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION. | benzimidazoles; biphenyls; carboxybiphenyl | angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic |
rosiglitazone | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | |
2-bromopalmitate | 2-bromohexadecanoic acid : A bromo fatty acid that is hexadecanoic (palmitic) acid carrying a single bromo substituent at position 2. 2-bromopalmitate: inhibitor of fatty acid oxidation; RN given refers to parent cpd | 2-bromocarboxylic acid; bromo fatty acid; long-chain fatty acid; straight-chain fatty acid | fatty acid oxidation inhibitor |
mk 767 | 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source | ||
anacardic acid | anacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities. anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor | hydroxy monocarboxylic acid; hydroxybenzoic acid | anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite |
farglitazar | farglitazar: a non-thiazolidinedione insulin sensitiser and PPARgamma agonist | ||
syringaresinol | (+)-syringaresinol : The (7alpha,7'alpha,8alpha,8'alpha)-stereoisomer of syringaresinol. | syringaresinol | antineoplastic agent |
oleic acid | oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry. Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed) | octadec-9-enoic acid | antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent |
epipinoresinol | epipinoresinol : An enantiomer of pinoresinol having (+)-(1R,3aR,4S,6aR)-configuration. | pinoresinol | marine metabolite; plant metabolite |
t 0070907 | T 0070907: a PPARgamma antagonist; structure in first source | carbonyl compound; organohalogen compound | |
gsk 3787 | |||
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide | 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source | ||
gw 7647 | GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group. GW 7647: a PPAR-alpha agonist; structure in first source | aryl sulfide; monocarboxylic acid; ureas | PPARalpha agonist |
psi-baptigenin | pseudobaptigenin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone and in which the phenyl group at position 3 is replaced by a 1,3-benzodioxol-5-yl group. | 7-hydroxyisoflavones; benzodioxoles | antiprotozoal drug; plant metabolite |
n-oleoylethanolamine | N-oleoylethanolamine: ceramidase inhibitor oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide. | endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1 | EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist |
pregna-4,17-diene-3,16-dione | pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor | 3-hydroxy steroid | androgen |
gw 1929 | GW 1929: activates peroxisome proliferator-activated receptor-gamma; structure in first source | benzophenones | |
l-165041 | 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: a PPAR-delta agonist has regulatory effects on a variety of adipokines, and these effects might explain some of their metabolic function. | aromatic ketone | |
gw 501516 | GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively. GW 501516: a selective PPARdelta agonist; structure in first source | 1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound | carcinogenic agent; PPARbeta/delta agonist |
tzd 18 | |||
gft505 | |||
gw 9578 | GW 9578: a peroxisome proliferator-activated receptor alpha agonist; structure in first source | ||
gw 7845 | GW 7845: ligand of the peroxisome proliferator-activated receptor-gamma; structure in first source | ||
naveglitazar | naveglitazar: LY-519818 is the (alpha-S)-isomer; an antidiabetic agent; structure in first source | aromatic ether | |
l 796449 | L 796449: a peroxisomal proliferator-activated receptor-gamma agonist; structure in first source | ||
gw0742 | GW 610742: structure in first source | monocarboxylic acid | |
3-chloro-4-(3-(7-propyl-3-trifluoromethyl-6-benzisoxazolyl)propylthio)phenylacetic acid | |||
ns-220 | |||
gw 590735 | 2-methyl-2-(4-(((4-methyl-2-(4-trifluoromethylphenyl)-thiazol-5-ylcarbonyl)amino)methyl)phenoxy)propionic acid: an HDLc raising agent; structure in first source | ||
aleglitazar | aleglitazar: a dual peroxisome PPAR-alpha and PPAR-gamma agonist for type 2 diabetes | ||
mbx-8025 | seladelpar: PPAR-delta agonist | ||
gw9508 | GW9508: structure in first source | aromatic amine | |
lj 529 | |||
bms 687453 | |||
amorfrutin a | amorfrutin A: an antidiabetic agent that inhibits NF-kappaB activation; structure in first source | stilbenoid | |
amorfrutin b | amorfrutin B: structure in first source | ||
gsk0660 | GSK0660: PPAR antagonist; structure in first source | sulfonamide | |
ly 518674 | LY 518674: a peroxisome proliferator-activated receptor alpha agonist; structure in first source |